Floatz logo

Patisiran

TTR-mediated Amyloidosis

Alnylam PharmaceuticalsPhase 3Dormant
A
80/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
72/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the TTR-mediated Amyloidosis cohort.

Asset / SponsorPhaseRating
Revusiran
Alnylam Pharmaceuticals
Phase 3BB
Patisiran
Alnylam Pharmaceuticals
Phase 3BB
Aln-Ttrsc02
Alnylam Pharmaceuticals
Phase 3BB
Revusiran
Alnylam Pharmaceuticals
Phase 3BB
Patisiran
Alnylam Pharmaceuticals
Phase 3BB

View all 12 →

Same molecule, other indications

Patisiran is also rated in:

Transthyretin AmyloidosisDormant
BBB
Indicative ·
72 / 100
View asset →
hereditary amyloidosisDormant
BB
Indicative ·
68 / 100
View asset →
hereditary amyloidosisDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →